Profil bibliographique

Johann Petrus Jordaan

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

3Publications signalées
424Citations signalées
0Affiliations récentes

Les domaines associés

Cancer Immunotherapy and BiomarkersCAR-T cell therapy researchAntifungal resistance and susceptibilityBreast Cancer Treatment StudiesMelanoma and MAPK Pathways

Les publications récentes

2017 conference-abstract OpenAlex

Extended survival analysis of ipilimumab for the treatment of advanced malignant melanoma in pretreated patients: Five-year long-term follow-up of the South African expanded access program.

Bernardo Leon Rapoport, Daniel Vorobiof, Lydia Dreosti, Adam L. Nosworthy et autres

84 Background: Ipilimumab is a human monoclonal IgG1 antibody against CTLA-4 that has been shown to prolong the overall survival of patients with advanced pretreated melanoma. In 2015, a retrospective, multi-centre, non-interventional analysis was performed on data collected from the ipilimumab expanded …

Afrique du Sud (code pays fourni par la source)

0 citations Journal of Clinical Oncology
2015 conference-abstract OpenAlex

Durable remissions with Ipilimumab in pretreated metastatic malignant melanoma (MMM) patients (pts): Results of a South African Expanded Access Program (EAP).

Daniel Vorobiof, Bernardo Leon Rapoport, Lydia Dreosti, Adam L. Nosworthy et autres

e20112 Background: This retrospective analysis reports data on demographics and outcomes of an ipilimumab South African EAP. Ipilimumab was given at a dose of 3 mg/kg intravenously every 3 weeks for 4 cycles to adults with MMM who failed at least 1 …

Afrique du Sud, us (code pays fourni par la source)

0 citations Journal of Clinical Oncology
Accès ouvert 2008 article OpenAlex

Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment

Kathy S. Albain, Shona Milon Nag, Germán Calderillo-Ruiz, Johann Petrus Jordaan et autres

PURPOSE: The objective of this phase III global study was to compare the efficacy of gemcitabine plus paclitaxel (GT) versus paclitaxel in patients with advanced breast cancer. It was designed as a pivotal study for the approval of G for a breast …

es (code pays fourni par la source)

424 citations Journal of Clinical Oncology
Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.